{"id":"https://openalex.org/W4381734495","doi":"https://doi.org/10.2337/db23-51-or","title":"51-OR: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity","display_name":"51-OR: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity","alternate_titles":[],"publication_year":2023,"publication_date":"2023-06-23","ids":{"openalex":"https://openalex.org/W4381734495","doi":"https://doi.org/10.2337/db23-51-or"},"language":"en","primary_location":{"id":"doi:10.2337/db23-51-or","doi":"https://doi.org/10.2337/db23-51-or","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db23-51-or","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4381734495"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010753663","display_name":"Carel Wynand le Roux","orcid":"https://orcid.org/0000-0001-5521-5445","observed_orcids":["https://orcid.org/0000-0001-5521-5445"]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"CAREL LE ROUX","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113734738","display_name":"O. Van de Steen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"OREN STEEN","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030205518","display_name":"Kathryn Jean Lucas","orcid":"https://orcid.org/0000-0003-1197-1403","observed_orcids":["https://orcid.org/0000-0003-1197-1403"]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"KATHRYN J. LUCAS","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018407864","display_name":"Elena Startseva","orcid":"https://orcid.org/0000-0002-9363-7056","observed_orcids":["https://orcid.org/0000-0002-9363-7056"]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"ELENA STARTSEVA","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004239136","display_name":"Anna Unseld","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"ANNA UNSELD","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036652363","display_name":"Anita M. Hennige","orcid":"https://orcid.org/0000-0002-5149-4966","observed_orcids":["https://orcid.org/0000-0002-5149-4966"]},"institutions":[{"id":"https://openalex.org/I4210138665","display_name":"Boehringer Ingelheim (Canada)","ror":"https://ror.org/031sxg258","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210138665"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"ANITA M. HENNIGE","raw_affiliation_strings":["Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin, Ireland, Toronto, ON, Canada, Morehead City, NC, Ingelheim, Germany, Biberach, Germany","institution_ids":["https://openalex.org/I4210138665"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210138665"],"apc_list":null,"apc_paid":null,"fwci":3.1383,"has_fulltext":false,"cited_by_count":27,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.92469245,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"72","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10489","display_name":"Regulation of Appetite and Obesity","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.8090000152587891},{"id":"https://openalex.org/keywords/overweight","display_name":"overweight","score":0.9829999804496765},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8320000171661377},{"id":"https://openalex.org/keywords/weight-change","display_name":"weight change","score":0.7260000109672546},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.6150000095367432},{"id":"https://openalex.org/keywords/energy-expenditure","display_name":"energy expenditure","score":0.6039999723434448},{"id":"https://openalex.org/keywords/energy-intake","display_name":"energy intake","score":0.6980000138282776},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.7059999704360962},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.527999997138977},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.3409999907016754},{"id":"https://openalex.org/keywords/efficacy","display_name":"efficacy","score":0.4230000078678131},{"id":"https://openalex.org/keywords/maintenance-dose","display_name":"maintenance dose","score":0.3400000035762787}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7794189453125},{"id":"https://openalex.org/C2780586474","wikidata":"https://www.wikidata.org/wiki/Q332428","display_name":"Overweight","level":3,"score":0.7418535947799683},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6563348174095154},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.573849618434906},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.5463711023330688},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4919116497039795},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.48543697595596313},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.4742540419101715},{"id":"https://openalex.org/C2778542361","wikidata":"https://www.wikidata.org/wiki/Q14904911","display_name":"Glucagon receptor","level":4,"score":0.4247402846813202},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.28182679414749146},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.27160513401031494},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.23162373900413513},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db23-51-or","doi":"https://doi.org/10.2337/db23-51-or","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db23-51-or","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4311822262","https://openalex.org/W4361190240","https://openalex.org/W4381376491","https://openalex.org/W4308387643","https://openalex.org/W4281787239","https://openalex.org/W4391544195","https://openalex.org/W2053470401","https://openalex.org/W3121704649","https://openalex.org/W3194756735","https://openalex.org/W4385441695"],"abstract_inverted_index":{"Glucagon":[0],"receptor":[1,11],"(GCGR)":[2],"agonism":[3,13],"increases":[4],"energy":[5,15],"expenditure":[6],"and":[7,41,145,208,215,223,226,234,272,299,318],"glucagon-like":[8],"peptide":[9],"1":[10],"(GLP-1R)":[12],"reduces":[14],"intake;":[16],"thus,":[17],"dual":[18],"GCGR/GLP-1R":[19],"agonists,":[20],"such":[21],"as":[22],"BI":[23,44,66,154,220,239,256,296,316,340],"456906,":[24],"may":[25],"be":[26],"more":[27],"effective":[28],"at":[29,97,114,174,246],"treating":[30],"obesity":[31],"than":[32],"mono":[33],"GLP-1R":[34],"agonists.":[35],"This":[36,51],"dose-finding":[37],"study":[38,55],"tested":[39],"efficacy":[40,346],"safety":[42,350],"of":[43,103,150,168,205,217,228,244,255,274,295,301,365],"456906":[45,67,155,221,240,257,297,317,341],"in":[46,315],"participants":[47],"(pts)":[48],"with":[49,59,179,347],"overweight/obesity.":[50],"double-blind,":[52],"placebo":[53],"(PBO)-controlled":[54],"(NCT04667377)":[56],"randomised":[57,121],"adults":[58],"BMI":[60,146],"\u226527":[61],"kg/m2":[62],"to":[63],"weekly":[64],"subcutaneous":[65],"(0.6,":[68],"2.4,":[69],"3.6,":[70],"4.8":[71,194,218,237,269,289,331],"mg)":[72],"or":[73,108],"PBO":[74,159,229,275,302,319],"for":[75],"46":[76,182,338],"weeks":[77,183],"(thereof":[78],"20-week":[79],"(W)":[80],"rapid,":[81],"bi-weekly":[82],"dose":[83,165,180,308],"escalation;":[84],"26-W":[85],"maintenance).":[86],"Primary":[87],"endpoint":[88],"was":[89,139,160,210,313],"bodyweight":[90],"(BW)":[91],"change":[92,170],"(%)":[93,171],"from":[94,112,172],"baseline":[95],"(BL)":[96],"W46.":[98,115,175,247],"Secondary":[99],"endpoints":[100],"included":[101],"proportion":[102],"pts":[104,119,151,222,258,298,303,320],"reaching":[105,233],"\u22655,":[106,206],"\u226510":[107,207],"\u226515%":[109,209],"BW":[110,142,169,177,202,242,344],"loss":[111,203,243,345],"BL":[113,135,173],"In":[116],"total,":[117],"387":[118],"were":[120,152,251],"(treated":[122],"set":[123,128],"[TS],":[124],"N=386;":[125],"full":[126],"analysis":[127],"[FAS],":[129],"N=384;":[130],"n\u224877":[131],"per":[132],"arm).":[133],"At":[134,200],"(FAS)":[136,204],"mean":[137],"age":[138],"49.1":[140],"years,":[141],"105.7":[143],"kg":[144],"37.1":[147],"kg/m2;":[148],"31.8%":[149],"male.":[153],"therapeutic":[156],"benefit":[157],"vs":[158,197,334],"shown":[161],"by":[162,212,253],"a":[163],"non-flat":[164],"response":[166],"curve":[167],"Mean":[176],"reduced":[178],"over":[181],"(FAS;":[184],"0.6":[185,260,280,322],"mg,":[186,189,192,195,261,264,267,270,281,284,287,290,323,326,329,332],"\u22126.2%;":[187],"2.4":[188,263,283,325],"\u221212.5%;":[190],"3.6":[191,266,286,328],"\u221213.2%;":[193],"\u221214.9%;":[196],"PBO,":[198,292,335],"\u22122.8%).":[199],"W46,":[201],"reached":[211],"82.8%,":[213],"68.8%":[214],"54.7%":[216],"mg":[219,238],"25.9%,":[224],"11.1%":[225],"5.6%":[227],"pts,":[230,276],"respectively.":[231],"Pts":[232],"staying":[235],"on":[236],"achieved":[241],"18.7%":[245],"Adverse":[248],"events":[249],"(AEs)":[250],"reported":[252],"90.9%":[254],"(TS;":[259,279,321],"90.9%;":[262],"89.7%;":[265],"92.2%;":[268],"90.9%)":[271],"75.3%":[273],"mainly":[277,306],"gastrointestinal":[278],"57.1%;":[282],"85.9%;":[285],"75.3%;":[288],"81.8%;":[291],"41.6%);":[293],"24.6%":[294],"3.9%":[300],"stopped":[304],"treatment,":[305],"during":[307],"escalation.":[309],"Serious":[310],"AE":[311],"incidence":[312],"similar":[314],"1.3%;":[324],"2.6%;":[327],"7.8%;":[330],"5.2%;":[333],"6.5%).":[336],"Over":[337],"weeks,":[339],"showed":[342],"substantial":[343],"no":[348],"unexpected":[349],"concerns.":[351],"Disclosure":[352],"C.Le":[353],"roux:":[354],"Advisory":[355],"Panel;":[356],"Novo":[357],"Nordisk,":[358],"Boehringer":[359,382,390,398],"Ingelheim":[360,383,391,399],"Inc.,":[361,367],"Lilly,":[362],"Herbalife":[363],"International":[364,384,392],"America,":[366],"Johnson":[368],"&":[369],"Johnson,":[370],"Medtronic,":[371],"GI":[372],"Dynamics,":[373],"Keyron":[374],"Ltd.":[375],"O.Steen:":[376],"None.":[377,379,387],"K.J.Lucas:":[378],"E.Startseva:":[380],"Employee;":[381,389],"GmbH.":[385,393],"A.Unseld:":[386],"A.M.Hennige:":[388],"Funding":[394],"Zealand":[395],"Pharma":[396],"A/S;":[397]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4381734495","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2023-06-24T00:00:00"}
